Current circulating SARS-CoV-2 lineages such as XFG (Stratus) and BA.3.2 (Cicada) explain the strong trader preference for no new variant of concern before 2027. XFG has dominated in the US, UK, and Europe since early 2025 without evidence of greater severity or immune escape that would trigger WHO designation, while BA.3.2 remains a low-risk variant under monitoring with limited spread. Recent seasonal rises in cases and hospitalizations align with typical fall patterns and existing strains rather than novel threats, and updated monovalent vaccines target these lineages effectively. Sustained population immunity from prior infections and vaccinations continues to limit the public-health impact of incremental mutations, supporting the view that a qualifying new variant of concern is unlikely to emerge and be declared within the remaining timeframe.